Skip to content
  • The group
      • Cenexi in a nutshell
      • Goal
      • Vision
      • Strategy
      • Sites
  • Expertise
    • MANUFACTURING AND PACKAGING

      • Sterile pharmaceutical forms
      • Non-sterile pharmaceutical forms
      • Special substances
    • PHARMACEUTICAL DEVELOPMENT AND INDUSTRIAL TRANSFER

      • Expertise and teams dedicated to transfer and development
  • News
  • Join us
      • Corporate culture
      • Recruitment policy
      • Jobs
      • Job postings
  • Contact us
  • English
    • Français
  • The group
      • Cenexi in a nutshell
      • Goal
      • Vision
      • Strategy
      • Sites
  • Expertise
    • MANUFACTURING AND PACKAGING

      • Sterile pharmaceutical forms
      • Non-sterile pharmaceutical forms
      • Special substances
    • PHARMACEUTICAL DEVELOPMENT AND INDUSTRIAL TRANSFER

      • Expertise and teams dedicated to transfer and development
  • News
  • Join us
      • Corporate culture
      • Recruitment policy
      • Jobs
      • Job postings
  • Contact us
  • English
    • Français
02/27/2024 Articles

Alain KIRCHMEYER, new CEO at Cenexi

Lire la suite
12/04/2023 Articles

Blue novembre: awareness actions at Cenexi

Lire la suite
11/02/2023 Articles

Pink October: Cenexi’s commitment to the fight against breast cancer

Lire la suite
10/05/2023 Articles

Jim McPherson, new CEO and President at Cenexi

Lire la suite
06/14/2023 Articles

World Blood Donor Day at Cenexi

Lire la suite
10/31/2022 Articles

Pink October: breast cancer awareness at Cenexi

Lire la suite
08/30/2022 Articles

Expertise in the production of lyophilized drugs at Cenexi

Lire la suite
05/13/2022 Articles

Cenexi will be at CPhI North America from May 17th to 19th!

Lire la suite
03/22/2022 Articles

A new milestone with the Crossject needle-free auto-injector

Lire la suite
02/09/2022 Press releases

Cenexi and Humanigen partnership: a promising treatment for severe forms of Covid-19

Lire la suite
01/18/2022 Press releases

The FDA authorizes Cenexi to produce ProvayBlue® (methylene blue) for the USA

Lire la suite
01/04/2022 Articles

Our best wishes for 2022!

Lire la suite

Production sites

Fontenay-sous-Bois (Headquarter)
52, rue Marcel et Jacques Gaucher
94120 Fontenay-sous-Bois
France
+33 1 43 94 88 00

Braine-l’Alleud
rue de la Papyree 2-4-6
1420 Braine-l’Alleud
Belgium
+32 2 386 13 01

Hérouville-Saint-Clair
2, rue Louis Pasteur
14200 Hérouville-Saint-Clair
France
+33 2 31 06 92 00

Osny
17, rue de Pontoise
95520 Osny
France
+33 1 34 20 44 20

  • Privacy Policy and legal information
  • Linkedin
  • Contact us
Logo agence maecia
Manage Cookie Consent
Ce site utilise des cookies et vous donne le contrôle sur ceux que vous souhaitez activer Découvrir la politique des données
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
Préferences
{title} {title} {title}
This site is registered on wpml.org as a development site.